Advances in RIPK1 kinase inhibitors (vol 13, 976435, 2022)

被引：0
|
作者：
Frontiers Prod Off [1 ]
机构：
[1] Frontiers Media SA, Lausanne, Switzerland
来源：
FRONTIERS IN PHARMACOLOGY | 2023年 / 13卷
关键词：
inhibitor; receptor interacting protein 1 (RIP1); programmed necrosis; necrosis; RIP1 (RIPK1);
D O I：
10.3389/fphar.2022.1123234
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Structure-based development of potent and selective type-II kinase inhibitors of RIPK1
    Qin, Ying
    Li, Dekang
    Qi, Chunting
    Xiang, Huaijiang
    Meng, Huyan
    Liu, Jingli
    Zhou, Shaoqing
    Gong, Xinyu
    Li, Ying
    Xu, Guifang
    Zu, Rui
    Xie, Hang
    Xu, Yechun
    Xu, Gang
    Zhang, Zheng
    Chen, Shi
    Pan, Lifeng
    Li, Ying
    Tan, Li
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (01) : 319 - 334
  • [22] Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2025, 16 (02): : 204 - 206
  • [23] Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
    Lauren Mifflin
    Dimitry Ofengeim
    Junying Yuan
    Nature Reviews Drug Discovery, 2020, 19 : 553 - 571
  • [24] Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3
    Chen, Xiaofei
    Zhuang, Chunlin
    Ren, Yibin
    Zhang, Hao
    Qin, Xia
    Hu, Longmiao
    Fu, Jing
    Miao, Zhenyuan
    Chai, Yifeng
    Li, Zheng-gang
    Zhang, Haibing
    Cai, Zhenyu
    Wang, Hong-yang
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (12) : 2095 - 2108
  • [25] Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis
    Jue Hou
    Jie Ju
    Zili Zhang
    Cong Zhao
    Zhanhui Li
    Jiyue Zheng
    Tian Sheng
    Hongjian Zhang
    Linkun Hu
    Xiaoliang Yu
    Wei Zhang
    Yangxin Li
    Meng Wu
    Haikuo Ma
    Xiaohu Zhang
    Sudan He
    Cell Death & Disease, 10
  • [26] RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development
    Bai, Yinliang
    Qiao, Yujun
    Li, Mingming
    Yang, Wenzhen
    Chen, Haile
    Wu, Yanqing
    Zhang, Honghua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [27] Virtual screening of flavonoids as potential RIPK1 inhibitors for neurodegeneration therapy
    Bepari, Asim Kumar
    Shatabda, Swakkhar
    Reza, Hasan Mahmud
    PEERJ, 2024, 12
  • [28] Inhibiting RIPK1 Kinase Activity Is Protective in Experimental Models of COPD
    Van Eeckhoutte, H. P.
    Donovan, C.
    Kim, R.
    Khan, H.
    Jayaraman, R.
    Dondelinger, Y.
    Delanghe, T.
    Beal, A.
    Geddes, B.
    Bertin, J.
    Vanden Berghe, T.
    Vandenabeele, P.
    Vanaudenaerde, B.
    Deforce, D.
    Skevin, S.
    Van Nieuwerburgh, F.
    Verhamme, F.
    Joos, G.
    Brusselle, G. G.
    Bertrand, M.
    Hansbro, P.
    Bracke, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [29] Role of the Kinase-Dependent Functions of RIPK1 in the Pathogenesis of COPD
    Van Eeckhoutte, H. P.
    Dondelinger, Y.
    Delanghe, T.
    Vandenabeele, P.
    Brusselle, G. G.
    Bertrand, M. J.
    Bracke, K. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [30] The Impact of RIPK1 Kinase Inhibition on Atherogenesis: A Genetic and a Pharmacological Approach
    Puylaert, Pauline
    Coornaert, Isabelle
    Neutel, Cedric H. G.
    Dondelinger, Yves
    Delanghe, Tom
    Bertrand, Mathieu J. M.
    Guns, Pieter-Jan
    De Meyer, Guido R. Y.
    Martinet, Wim
    BIOMEDICINES, 2022, 10 (05)
12345